NASDAQ:PRNB Principia Biopharma (PRNB) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free PRNB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$100.05▼$100.0550-Day Range$99.95▼$100.2752-Week Range$25.35▼$101.89VolumeN/AAverage Volume729,676 shsMarket Capitalization$3.32 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Principia Biopharma alerts: Email Address Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… About Principia Biopharma Stock (NASDAQ:PRNB)Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… PRNB Stock News HeadlinesMay 28, 2023 | bizjournals.comPrincipia College names new presidentMay 5, 2023 | theguardian.comCBI appoints ethics consultancy Principia Advisory in fight for survivalApril 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 22, 2023 | benzinga.comTruist Securities Downgrades 9 Meters Biopharma to Hold, Announces $38 Price TargetJanuary 17, 2023 | msn.comWooly mammoth tusk discovered on Principia College campusOctober 12, 2022 | finance.yahoo.comDodge Construction Network Acquires Principia Consulting, Expanding Dodge Advisory Services’ CapabilitiesOctober 1, 2022 | sfgate.comPrincipia earns top US News & World Report ratingJuly 7, 2022 | investing.comPrincipia Biopharma Inc (PRNB)April 23, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 5, 2022 | chron.comDance therapy: In-person performances back at PrincipiaMarch 18, 2022 | msn.comWhere to find the Golden Order Principia in Elden RingJanuary 10, 2022 | news.yahoo.comLebanon's Skobel signs with PrincipiaOctober 1, 2021 | chron.comPrincipia College earns honorsJuly 31, 2021 | nasdaq.comPrincipia Biopharma Inc. Common Stock (PRNB)See More Headlines Receive PRNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Principia Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2020Today4/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PRNB CUSIPN/A CIKN/A Webwww.principiabio.com Phone650-416-7700FaxN/AEmployees65Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-23.08% Return on Assets-21.11% Debt Debt-to-Equity RatioN/A Current Ratio17.01 Quick Ratio17.01 Sales & Book Value Annual Sales$35.16 million Price / Sales94.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.95 per share Price / Book9.14Miscellaneous Outstanding Shares33,209,000Free FloatN/AMarket Cap$3.32 billion OptionableNot Optionable Beta0.86 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Alan B. Colowick Ph.D. (Age 57)M.D., M.P.H., Exec. Chairman Mr. Martin Babler (Age 54)CEO & Director Mr. Christopher Y. Chai (Age 52)Chief Financial Officer Ms. Stefani A. Wolff (Age 57)Chief Devel. Officer Dr. David M. Goldstein (Age 53)Chief Scientific Officer Key CompetitorsPrestige Consumer HealthcareNYSE:PBHAxsome TherapeuticsNASDAQ:AXSMBausch Health CompaniesNYSE:BHCUltragenyx PharmaceuticalNASDAQ:RAREXenon PharmaceuticalsNASDAQ:XENEView All Competitors PRNB Stock Analysis - Frequently Asked Questions How were Principia Biopharma's earnings last quarter? Principia Biopharma Inc. (NASDAQ:PRNB) posted its quarterly earnings data on Thursday, August, 6th. The company reported $0.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.03) by $1.34. The business had revenue of $50 million for the quarter, compared to analysts' expectations of $50 million. What other stocks do shareholders of Principia Biopharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Principia Biopharma investors own include Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Cisco Systems (CSCO), Gilead Sciences (GILD), Micron Technology (MU), QUALCOMM (QCOM), VBI Vaccines (VBIV), ImmunoGen (IMGN) and Taiwan Semiconductor Manufacturing (TSM). When did Principia Biopharma IPO? Principia Biopharma (PRNB) raised $75 million in an initial public offering on Friday, September 14th 2018. The company issued 4,700,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities served as the underwriters for the IPO and Baird was co-manager. This page (NASDAQ:PRNB) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Principia Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
